论文部分内容阅读
目的观察黛立新联合奥美拉唑、莫沙比利治疗功能性消化不良(FD)的临床疗效。方法采取随机对照研究,80例功能性消化不良患者,随机分为二组,A组40例,口服奥美拉唑胶囊40mg,2次/d;莫沙比利片5mg,3次/d;B组40例,口服奥美拉唑胶囊40mg,2次/d;口服莫沙比利5mg,3次/d;黛立新片,每天口服2次,早晨及中午各1片。结果黛立新联合奥美拉唑、莫沙比利治疗组的有效率率87.5%,显效率70.0%,明显优于奥美拉唑联合莫沙比利组,有显著性差异(P<0.05),治疗后均未发现明显不良反应。结论黛立新能有效缓解功能性消化不良(FD)的症状,疗效明显、安全可靠。
Objective To observe the clinical efficacy of Dai Lixin combined with omeprazole and mosapride in the treatment of functional dyspepsia (FD). Methods A randomized controlled study of 80 patients with functional dyspepsia was randomly divided into two groups. Group A (n = 40) received Omeprazole capsule 40 mg twice a day, mosapride 5 mg thrice a day, Group B 40 cases, oral omeprazole capsule 40mg, 2 times / d; oral Mosapride 5mg, 3 times / d; Dai Li new tablets, oral 2 times a day, morning and noon of a. Results The effective rate was 87.5% and the effective rate was 70.0% in the combination group and omeprazole and mosapride group, which was significantly better than that of omeprazole and mosapride group (P <0.05) No significant adverse reactions were found after treatment. Conclusion Dai Lixin can effectively alleviate the symptoms of functional dyspepsia (FD), the effect is obvious, safe and reliable.